Clinical Trial Update: Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating a 26-valent pneumococcal conjugate vaccine has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• 26-valent Pneumococcal Conjugate Vaccine (Pneumococcal conjugate vaccine, 26-valent)

Snippet

Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Conditions: Pneumococcal Vaccines | Phase 1, Phase 2 | Status: COMPLETED